Evidence map›Paper›PMID 40199821›Full record

SynthesisObesity surgery2025

Endoscopic Sleeve Gastroplasty for the Treatment of Metabolic Syndrome: A Systematic Review and Meta-analysis.

Mark Hanscom, Muhammad Usman Baig, Drew Wright, Laith Baqain, Kate Elise Johnson, Vivek Kumbhari, Shelby Sullivan, Barham Abu Dayyeh, SriHari Mahadev, Carolyn Newberry and 4 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Observational
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. A moonshot for diabetes and obesity.iGIE : innovation, investigation and insights · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mark HanscomWeill Cornell Medicine, New York, NY, USA. mah4040@med.cornell.edu.
Muhammad Usman BaigWeill Cornell Medicine, New York, NY, USA.
Drew WrightWeill Cornell Medicine, New York, NY, USA.
Laith BaqainWeill Cornell Medicine, New York, NY, USA.
Kate Elise JohnsonWeill Cornell Medicine, New York, NY, USA.
Vivek KumbhariMayo Clinic, Rochester, USA.
Shelby SullivanDartmouth-Hitchcock Medical Center, Lebanon, USA.
Barham Abu DayyehCedars-Sinai Medical Center, Los Angeles, USA.
SriHari MahadevWeill Cornell Medicine, New York, NY, USA.
Carolyn NewberryWeill Cornell Medicine, New York, NY, USA.
Kartik SampathWeill Cornell Medicine, New York, NY, USA.
David Carr-LockeWeill Cornell Medicine, New York, NY, USA.
Christopher ThompsonBrigham and Women's Hospital, Boston, USA.
Reem SharaihaWeill Cornell Medicine, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEndoscopic sleeve gastroplasty (ESG) is an incisionless weight loss procedure that has been demonstrated to be safe and effective for the treatment of obesity; however, the efficacy of ESG for the treatment of comorbid type 2 diabetes mellitus (T2DM) and other components of metabolic syndrome (MetS) has been less well studied. We aimed to conduct a systematic review and meta-analysis of available literature to evaluate the outcomes of ESG on T2DM and MetS.

methodsBibliographic databases were systematically searched for studies assessing the outcomes of ESG on T2DM and MetS. Studies were included if they reported at least one objective outcome related to T2DM or other components of MetS, including hyperlipidemia (HLD), hypertriglyceridemia, and hypertension (HTN). This study was deemed IRB exempt.

resultsTen studies with 4320 patients were included. At 12 months, ESG was associated with significant improvements in T2DM, HLD, and HTN, with risk difference of - 0.72 [95% CI, - 0.87 to - 0.58, p < 0.00001], - 0.65 [95% CI, - 0.78 to - 0.52, p < 0.00001], and - 0.60 [95% CI, - 0.66 to - 0.53, p < 0.00001], respectively. Disease improvement was defined as patients being able to stop some or all of their related treatment medications. Additionally, there were significant reductions in hemoglobin A1c (HGBA1c), fasting blood glucose, homeostatic model assessment for insulin resistance (HOMA-IR), low-density lipoprotein, and triglycerides.

conclusionsESG is an effective modality for the treatment of comorbid T2DM and MetS in patients with obesity. Additional studies are needed to establish long-term responses and to compare ESG against established pharmacologic and surgical techniques.

Indexed as

Diabetes Mellitus, Type 2GastroplastyGastroscopyMetabolic SyndromeObesity, MorbidHumansTreatment OutcomeWeight LossEBMTsEndoscopic bariatric and metabolic therapiesMetabolic syndromeType 2 diabetes mellitus

Identifiers

PMID40199821

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.